Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Centre for Medicines Discovery, Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, UK.
J Neurochem. 2024 Feb;168(2):115-127. doi: 10.1111/jnc.16030. Epub 2023 Dec 12.
While unbiased proteomics of human cerebrospinal fluid (CSF) has been used successfully to identify biomarkers of amyotrophic lateral sclerosis (ALS), high-abundance proteins mask the presence of lower abundance proteins that may have diagnostic and prognostic value. However, developments in mass spectrometry (MS) proteomic data acquisition methods offer improved protein depth. In this study, MS with library-free data-independent acquisition (DIA) was used to compare the CSF proteome of people with ALS (n = 40), healthy (n = 15) and disease (n = 8) controls. Quantified protein groups were subsequently correlated with clinical variables. Univariate analysis identified 7 proteins, all significantly upregulated in ALS versus healthy controls, and 9 with altered abundance in ALS versus disease controls (FDR < 0.1). Elevated chitotriosidase-1 (CHIT1) was common to both comparisons and was proportional to ALS disability progression rate (Pearson r = 0.41, FDR-adjusted p = 0.035) but not overall survival. Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1; upregulated in ALS versus healthy controls) was proportional to disability progression rate (Pearson r = 0.53, FDR-adjusted p = 0.003) and survival (Kaplan Meier log-rank p = 0.013) but not independently in multivariate proportional hazards models. Weighted correlation network analysis was used to identify functionally relevant modules of proteins. One module, enriched for inflammatory functions, was associated with age at symptom onset (Pearson r = 0.58, FDR-adjusted p = 0.005) and survival (Hazard Ratio = 1.78, FDR = 0.065), and a second module, enriched for endoplasmic reticulum proteins, was negatively correlated with disability progression rate (r = -0.42, FDR-adjusted p = 0.109). DIA acquisition methodology therefore strengthened the biomarker candidacy of CHIT1 and UCHL1 in ALS, while additionally highlighted inflammatory and endoplasmic reticulum proteins as novel sources of prognostic biomarkers.
虽然使用无偏蛋白组学对人脑脊液(CSF)进行分析已成功地鉴定出肌萎缩侧索硬化症(ALS)的生物标志物,但高丰度蛋白质掩盖了可能具有诊断和预后价值的低丰度蛋白质的存在。然而,质谱(MS)蛋白质组学数据采集方法的发展提供了更高的蛋白质深度。在这项研究中,使用无库的质谱数据非依赖性采集(DIA)方法比较了 ALS 患者(n=40)、健康对照者(n=15)和疾病对照者(n=8)的 CSF 蛋白质组。随后,将定量蛋白质组与临床变量相关联。单变量分析鉴定出 7 种蛋白质,它们在 ALS 与健康对照组之间均显著上调,9 种蛋白质在 ALS 与疾病对照组之间的丰度发生改变(FDR<0.1)。升高的几丁质酶 1(CHIT1)在这两个比较中均很常见,并且与 ALS 残疾进展率呈比例关系(Pearson r=0.41,经 FDR 调整的 p=0.035),但与总生存期无关。泛素羧基末端水解酶同工酶 L1(UCHL1;在 ALS 与健康对照组中上调)与残疾进展率呈比例关系(Pearson r=0.53,经 FDR 调整的 p=0.003)和生存(Kaplan-Meier 对数秩检验 p=0.013),但在多变量比例风险模型中并不独立。加权相关网络分析用于鉴定蛋白质功能相关模块。一个富含炎症功能的模块与症状发作年龄(Pearson r=0.58,经 FDR 调整的 p=0.005)和生存(风险比=1.78,FDR=0.065)相关,另一个富含内质网蛋白的模块与残疾进展率呈负相关(r=-0.42,经 FDR 调整的 p=0.109)。因此,DIA 采集方法增强了 CHIT1 和 UCHL1 在 ALS 中的生物标志物候选物的地位,同时还强调了炎症和内质网蛋白作为新的预后生物标志物来源。